PharmaEssentia Corporation PharmaEssentia Corporation

PharmaEssentia Corporation

6446

Classement en actions #1442
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Prix de l'action
$36.89
Capitalisation boursière
$15.25B
Changement (1 jour)
-1.28%
Changement (1 an)
144.12%
Pays
TW
Échange PharmaEssentia Corporation (6446)

Catégorie

Healthcare
Ratio P/S pour PharmaEssentia Corporation (6446)
Ratio P/S au October 2026 TTM : 23.96
Selon les derniers rapports financiers et le cours de l'action de PharmaEssentia Corporation, le ratio cours/ventes actuel (TTM) est 23.96. À la fin de 2023, le ratio P/S était de 22.06.
Historique du ratio P/S pour PharmaEssentia Corporation de 2010 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
2026 (TTM) 23.96 16.52%
2024 20.56 -6.80%
2023 22.06 -53.07%
2022 47.01 -58.98%
2021 114.59 181.19%
2020 40.75 -46.81%
2019 76.61 -94.54%
2018 1.40K -81.75%
2017 7.68K 27.57%
2016 6.02K 95.48%
2015 3.08K 61.64%
2014 1.91K 276.50%
2013 506.34 -45.75%
2012 933.30 -41.98%
2011 1.61K 237.00%
2010 477.29 0.00%
Ratio P/S pour des entreprises similaires ou concurrentes